Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Emerging Growth Conference (April 2025)
19 slides from Evofem Biosciences's conference presentation, Apr 17, 2025
Slide 1: Emerging Growth Conference
EMERGING GROWTH CONFERENCE APRI L 17, 2025 AMY RASKOPF, CHIEF BUSINESS DEVELOPMENT OFFICER KATHY GALLO-DOYLE, HEAD OF COMMERCIAL OPERATIONS OTCQB: EVFM
Slide 2: Forward-Looking Statements
F O R W A R D - L O O K I N G S TAT E M E N T S This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” ”will
Slide 3: Evofem: Women's Sexual and Reproductive Health Innovation
E V O F E M : W O M E N ’ S S E X U A L A N D R E P R O D U C T I V E H E A LT H I N N O V AT I O N U.S. biopharma company generating revenues from two FDA-approved innovative products that address unmet needs in women’s sexual and reproductive health • Birth Control: hormone-free, on-demand prescri
Slide 4: Evofem Is Leading the Revolution
EVOFEM IS LEADING THE REVOLUTION Innovative women’s reproductive and sexual health solutions ® THE FIRST AND ONLY ON-DEMAND, NON- HORMONAL PRESCRIPTION CONTRACEPTIVE VAGINAL GEL • Vaginal pH Modulator • Hormone-free • FDA-approved for prevention of pregnancy • Woman-controlled • Used only when you n
Slide 5: MOA - PHEXXI Is a pH Modulator
M O A - P H E X X I I S A p H M O D U L AT O R Optimal vaginal pH levels can range from 3.5 – 4.5 When semen (pH 7.1-8) enters the vagina, it raises the environmental pH level Allows sperm to be mobile and swim up the reproductive canal PHEXXI keeps vaginal pH in the optimal range Among subjects who
Slide 6: PHEXXI In Vitro Demonstration of Sperm Motility
P H E X X I ® I N V I T R O D E M O N S T R AT I O N O F S P E R M M O T I L I T Y SPERM WITHOUT PHEXXI IN VITRO SPERM WITH PHEXXI IN VITRO TO VIEW THE VIDEO, PLEASE VISIT HTTPS://WWW.YOUTUBE.COM/WATCH?V=H8AOXANPZYY (TIME STAMP 4:25) 6
Slide 7: 43.3M Potential PHEXXI Users in the U.S.
43.3M POTENTIAL PHEXXI USERS IN THE U.S.1 U.S. MARKET BY CONTRACEPTIVE METHOD 1 (M ILLIO NS) 10 0% Non-Prescription Contraceptive 10.3M women use non-prescription contraceptives Non-Rx methods: barrier methods; withdrawal; periodic abstinence; tracking; other 90 % 10.3 80 % No Contraceptive 13.0M wo
Slide 8: $470M PHEXXI Annual Net Sales Per 1% Market Share
EVERY 1% MARKET SHARE IN THE U.S. ADDRESSABLE MARKET REPRESENTS SIGNIFICANT PHEXXI NET PRODUCT SALES $362.17 Gross WAC per box of 12 PHEXXI applicators1 x5 $470 M boxes of PHEXXI dispensed (on avg.) per woman each year PHEXXI ANNUAL $217.30 NET SALES Gross-to-Net Net to Evofem x 433,000 adjustments
Slide 9: Delivering Ongoing Net Product Sales Growth
DELIVERING ONGOING NET PRODUCT SALES GROWTH $25. 0 $20. 0 $19.4 $18.2 $16.8 $15. 0 IN MILLIONS $8.2 $10. 0 $5.0 $- FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 Launched PHEXXI Sept. 2020 No marketing spend since Q4 2022 APRIL 17, 2025 9
Slide 10: PHEXXI Sales Coverage
PHEXXI SALES COVERAGE Field Coverage (n=16) Virtual Coverage Strategic Initiatives Student Health & Residency Programs APRIL 17, 2025
Slide 11: Activating PHEXXI Utilization with Select Patient Types
A C T I V AT I N G P H E X X I U T I L I Z AT I O N W I T H S E L E C T PAT I E N T T Y P E S Not using a prescription contraceptive Living with depression and anxiety Postpartum mother Struggles with her weight In need of non-systemic contraception Cancer survivor Wants non-hormonal WE ARE SUCCESSF
Slide 12: Changing the Contraceptive Counseling Conversation
C H A N G I N G T H E C O N T R A C E P T I V E C O U N S E L I N G C O N V E R S AT I O N APRIL 17, 2025 12
Slide 13: Multichannel Marketing
M U LT I C H A N N E L M A R K E T I N G Enhancing promotional reach with minimal spend by tapping into social media, key conference opportunities, and tactical collateral ON TRACK TO BECOME #1 FOLLOWED CONTRACEPTIVE BRAND A P R I L 1 7 , 2 ON 025 IG 13
Slide 14: The GLP-1 Opportunity
T H E G L P - 1 O P P O R T U N I T Y: $ 2 3 3 . 5 M I L L I O N TA M 30 M GLP-1 users X $217.30 in the U.S. by 20301 net to Evofem per (JP Morgan analyst forecast) 1.1 M Women box of 12 PHEXXI 14% Women of Reproductive Age using OCs on GLP-1s using OCs of Women of Reproductive Age use These women a
Slide 15: Synergistic Women's Health Acquisition
S Y N E R G I S T I C W O M E N ’ S H E A LT H A C Q U I S I T I O N • Acquired in July 2024 from Lupin • Synergistic women’s health product • Aligns with strategic focus and leverages sales force • Both SOLOSEC and PHEXXI address the vaginal biome • $20M annual net sales run rate pre-Covid from BV
Slide 16: SOLOSEC: Two FDA-Approved Indications
S O L O S E C : T W O F D A - A P P R O V E D I N D I C AT I O N S B A C T E R I A L VA G I N O S I S ( B V ) I N F E M A L E S 1 2 A N D O L D E R • BV is the most common vaginal condition in women ages 15-44 • Raises pH of the vagina, which upsets the balance of the natural vaginal BV affects micr
Slide 17: Strong IP with Multiple Orange Book-Listed Patents
S T R O N G I P W I T H M U LT I P L E O R A N G E B O O K - L I S T E D PAT E N T S • Four Orange Book -listed patents afford protection into 2033 • White paper by US regulatory expert* delineates hurdles to potential generic entry stemming from PHEXXI’s localized MOA and absence of PK profile, pre
Slide 18: In Summary
IN SUMMARY We are executing our strategy to improve women’s lives through innovative sexual and reproductive health products that address unmet and underserved medical needs The first and only FDA-approved hormone-free, on demand prescription contraceptive vaginal gel - Approved and launched by Evof
Slide 19: Thank You
QUESTIONS? REACH OUT! IR@EVOFEM.COM THANK YOU S C I E N C E W I T H A S O U L E V F M
Evofem Biosciences — Emerging Growth Conference (April 2025) on 6ix